2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

786-O cell

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

3

Peptides

3

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10331
    Regorafenib
    Maximum Cited Publications
    87 Publications Verification

    BAY 73-4506

    		 VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
    Regorafenib
  • HY-111431
    p-Cresyl sulfate
    5+ Cited Publications

    p-Tolyl sulfate

    		 JNK p38 MAPK Reactive Oxygen Species (ROS) Metabolic Disease
    p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways .
    p-Cresyl sulfate
  • HY-112055
    DIM-C-pPhOH
    5+ Cited Publications

    		 Nuclear Hormone Receptor 4A/NR4A Apoptosis Cancer
    DIM-C-pPhOH is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhOH inhibits cancer cell growth and mTOR signaling, induce apoptosis and cellular stress. DIM-C-pPhOH reduces cell proliferation with IC50 values of 13.6 μM and 13.0 μM for ACHN cells and 786-O cells, respectively .
    DIM-C-pPhOH
  • HY-138556
    GPX4-IN-2

    		Drug Intermediate Glutathione Peroxidase Cancer
    GPX4-IN-2 is an intermediate of GPX4-IN-1 (HY-138544). GPX4-IN-1 has shown antiproliferative activity and can be used for cancer research .
    GPX4-IN-2
  • HY-10331A
    Regorafenib monohydrate
    Maximum Cited Publications
    87 Publications Verification

    BAY 73-4506 monohydrate

    		 VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
    Regorafenib monohydrate
  • HY-W195984
    Z57346765
    1 Publications Verification

    		 Phosphoglycerate Kinase (PGK) Cancer
    Z57346765 is an inhibitor that targets the ADP-binding pocket of PGK1, with a Kd of 20.9 μM for human PGK1, and exhibits anticancer activity. Z57346765 reduces the activity of the metabolic enzyme PGK1 during glycolysis, regulates lipid peroxidation and cancer cell proliferation, and promotes lipid peroxidation in cervical cancer cells. Z57346765 inhibits the proliferation of cervical cancer and clear cell renal cell carcinoma cells in xenograft mouse models, and induces the expression of genes associated with cell metabolism, DNA replication and cell cycle. Z57346765 is used in research related to cervical cancer, clear cell renal cell carcinoma and breast cancer .
    Z57346765
  • HY-159644
    Casdatifan

    AB521

    		 HIF/HIF Prolyl-Hydroxylase VEGFR Cancer
    Casdatifan (AB521) is an orally active and selective allosteric small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α). Casdatifan inhibits pro-tumor gene transcription by blocking the heterodimerization of HIF-2α with ARNT, and significantly suppresses tumor growth in clear cell renal cell carcinoma (ccRCC) models either as a monotherapy or in combination with agents such as Zimberelimab (HY-P99109). Casdatifan is applicable for the research of ccRCC .
    Casdatifan
  • HY-P2324
    Gramicidin A
    1 Publications Verification

    		 Bacterial HIF/HIF Prolyl-Hydroxylase Antibiotic Infection Cancer
    Gramicidin A is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A induces degradation of hypoxia inducible factor 1 α (HIF-1α) .
    Gramicidin A
  • HY-112056
    DIM-C-pPhCO2Me
    1 Publications Verification

    		 Nuclear Hormone Receptor 4A/NR4A Apoptosis DAPK Isocitrate Dehydrogenase (IDH) PERK Cancer
    DIM-C-pPhCO2Me is a nuclear receptor 4A1 (NR4A1) antagonist. DIM-C-pPhCO2Me induces Apoptosis. DIM-C-pPhCO2Me decreases PAX3-FOXO1A, N-Myc, Rassf4, MyoD1, Grem1, and DAPK1 proteins. DIM-C-pPhCO2Me decreases expression of TXNDC5 and IDH1, induces markers of ER stress (CHOP, ATF4 and p-PERK). DIM-C-pPhCO2Me inhibits renal cell carcinoma, breast cancer. DIM-C-pPhCO2Me can also be used in rhabdomyosarcoma research .
    DIM-C-pPhCO2Me
  • HY-157231A
    HC-5404-Fu

    		PERK Cancer
    HC-5404-Fu is an orally active PERK inhibitor with an IC50 of 0.001 μM against human PERK. HC-5404-Fu blocks PERK activation induced by VEGFR-TKI and disrupts the adaptive stress response triggered by VEGFR-TKI. HC-5404-Fu enhances anti-angiogenic effects by inhibiting newly formed and mature tumor blood vessels in renal cell carcinoma models. HC-5404-Fu can be used in research related to renal cell carcinoma .
    HC-5404-Fu
  • HY-153016
    HIF-2α agonist 2
    1 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology
    HIF-2α agonist 2 (compound 10) is a HIF-2α agonist with an EC50 value of 1.68 μM at the dose of 20 μM. HIF-2α agonist 2 is non-cytotoxic against 786-O-HRE-Luc cells. HIF-2α agonist 2 can be used for oxygen metabolism research .
    HIF-2α agonist 2
  • HY-155374
    PP5-IN-1

    		Phosphatase Apoptosis Caspase Cancer
    PP5-IN-1 is a competitive and selective serine/threonine protein phosphatase 5 (PP5) inhibitor with a Ki value of 244 nM. PP5-IN-1 induces extrinsic apoptosis (Apoptosis), disrupts the integrity of complex II, and activates Caspase 8. PP5-IN-1 can be used in research related to clear cell renal cell carcinoma .
    PP5-IN-1
  • HY-145835
    PERK-IN-5

    		PERK Cancer
    PERK-IN-5 is a highly potent, selectively and orally bioavailable PERK inhibitor (IC50s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model .
    PERK-IN-5
  • HY-165245
    SBI-183

    		Transmembrane Glycoprotein Cancer
    SBI-183 is an orally active inhibitor of QSOX1 (Kd: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .
    SBI-183
  • HY-126710
    OU749

    		γ-Glutamyl Transferase (GGT) Cancer
    OU749 is a potent γ-glutamyl transpeptidase (GGT) inhibitor with a Ki value of 17.6 µM. OU749 shows cytotoxicity .
    OU749
  • HY-176508
    KDX1381

    		Casein Kinase Cancer
    KDX1381 is a bivalent CK2α inhibitor (IC50: 17 nM, KD: 54 nM). KDX1381 has antitumor activity in mouse 786-O and A375 tumor xenograft models. KDX1381 combined with VEGFR inhibitors or DNA damaging agents enhances antitumor efficacy in mouse hepatocellular carcinoma and glioma models .
    KDX1381
  • HY-161096
    Antitumor agent-127

    		ROR Cancer
    Antitumor agent-127 (compound 1) is a parent macrocyclic peptide. Antitumor agent-127 displays nanomolar cell-based binding to ROR1 and relatively good internalization in 786-O and MDA-MB-231 tumor cell lines .
    Antitumor agent-127
  • HY-111431AR
    p-Cresyl sulfate potassium (Standard)

    p-Tolyl sulfate potassium (Standard)

    		 JNK p38 MAPK Reactive Oxygen Species (ROS) Reference Standards Metabolic Disease
    p-Cresyl sulfate (potassium) (Standard) is the analytical standard of p-Cresyl sulfate (potassium). This product is intended for research and analytical applications. p-Cresyl sulfate (p-Tolyl sulfate) potassium is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate potassium shows antiproliferation activity. p-Cresyl sulfate potassium increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate potassium induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways .
    p-Cresyl sulfate potassium (Standard)
  • HY-170675
    Ferroptosis-IN-13

    		Ferroptosis Cancer
    Ferroptosis-IN-13 (compound NY-26) is a ferroptosis inhibitor. Ferroptosis-IN-13 inhibits RSL3(HY-100218A)-induced ferroptosis in 786-O cells with an EC50 value of 62 nM .
    Ferroptosis-IN-13
  • HY-169298
    Ferroptosis-IN-15

    		Ferroptosis Cancer
    Ferroptosis-IN-15 (compound 12) is a potent inhibitor of ferroptosis, with the EC50s of 0.76 and 0.67 μM in A375 cells and 786-O cells, respectively.Ferroptosis-IN-15 is a potential iron chelator and radical trapping antioxidant .
    Ferroptosis-IN-15
  • HY-168707
    CK2-IN-14

    		Casein Kinase Cancer
    CK2-IN-14 (Compound 10b) is an inhibitor for cyclin kinase 2α with an IC50 of 36.7 nM. CK2-IN-14 inhibits the growth of cancer cell 786-O and U937 with GI50 of 7.3 μM and 7.5 μM .
    CK2-IN-14
  • HY-111431R
    p-Cresyl sulfate (Standard)

    p-Tolyl sulfate (Standard)

    		 Reference Standards JNK p38 MAPK Reactive Oxygen Species (ROS) Metabolic Disease
    Platycodin D (Standard) is the analytical standard of Platycodin D. This product is intended for research and analytical applications. Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D .
    p-Cresyl sulfate (Standard)
  • HY-10331B
    Regorafenib mesylate

    BAY 73-4506 mesylate

    		 VEGFR PDGFR RET Raf c-Kit FGFR Autophagy Tie Cancer
    Regorafenib (BAY 73-4506) mesylate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib mesylate shows very robust antitumor and antiangiogenic activity .
    Regorafenib mesylate
  • HY-10331AR
    Regorafenib monohydrate (Standard)

    BAY 73-4506 monohydrate (Standard)

    		 Reference Standards VEGFR Autophagy PDGFR Raf RET FGFR c-Kit Tie Cancer
    Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity .
    Regorafenib monohydrate (Standard)
  • HY-10331R
    Regorafenib (Standard)

    BAY 73-4506 (Standard)

    		 Reference Standards VEGFR Autophagy PDGFR Raf RET c-Kit FGFR Tie Cancer
    Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity .
    Regorafenib (Standard)
  • HY-170959
    NYY-6a

    		Ferroptosis Neurological Disease Metabolic Disease
    NYY-6a is a Ferroptosis inhibitor. NYY-6a shows significant inhibitory activity against RSL3-induced ferroptosis across 786-O and HT-1080 cells with EC50s of 52 and 50 nM, respectively. NYY-6a functions as a radical trapping antioxidant (RTA) with efficacy of diminishing lipid peroxidation comparable to ferrostatin-1 and liproxtatin-1. NYY-6a is potential for ferroptosis related pathologies reasearch .
    NYY-6a
  • HY-P2324A
    Gramicidin A TFA

    		Antibiotic Bacterial Infection
    Gramicidin A (TFA) is a peptide component of gramicidin, an antibiotic mixture originally isolated from B. brevis. Gramicidin A (TFA) is a highly hydrophobic channel-forming ionophore that forms channels in model membranes that are permeable to monovalent cations. Gramicidin A (TFA) induces degradation of hypoxia inducible factor 1 α (HIF-1α) .
    Gramicidin A TFA
  • HY-145835A
    (S)-PERK-IN-5

    		PERK Infection Cancer
    (S)-PERK-IN-5 is the S-enantiomer of PERK-IN-5. (S)-PERK-IN-5 (example 39) is a PERK inhibitor, with an IC50 of 0.101-0.250 μM .
    (S)-PERK-IN-5
  • HY-186143
    KY0418

    		Glutathione Peroxidase Ferroptosis Cancer
    KY0418 is a selective GPX4 inhibitor. KY0418 selectively and covalently modifies the selenocysteine residue of GPX4 and inhibits GPX4 activity. KY0418 induces ferroptosis and suppresses cell proliferation. KY0418 can be used for the study of ferroptosis and cancer .
    KY0418
  • HY-181270
    RH01504

    		HIF/HIF Prolyl-Hydroxylase Cancer
    RH01504 is a HIF2α inhibitor with a Kd value of 5.42 nM against human HIF2α. RH01504 inhibits the growth of renal cancer cells. RH01504 can be used in research related to renal cell carcinoma .
    RH01504
  • HY-W470101
    HIF-2α-IN-17

    		HIF/HIF Prolyl-Hydroxylase Apoptosis HSP Caspase Cancer
    HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma .
    HIF-2α-IN-17
  • HY-181955
    MS1129

    		Apoptosis DNA Methyltransferase HIF/HIF Prolyl-Hydroxylase Caspase Cancer
    MS1129 is a DNMT degrader that induces proteasomal degradation of DNMT1, DNMT3A and DNMT3B proteins. MS1129 upregulates TRAIL, DR4 and DR5 proteins, downregulates the decoy receptor DcR2, and activates TRAIL-dependent apoptosis via the HIF-1/2 and Caspase-10 pathways. MS1129 is applicable to the research of VHL-deficient clear cell renal cell carcinoma .
    MS1129
  • HY-183583
    HIF-2α-IN-18

    		HIF/HIF Prolyl-Hydroxylase Cancer
    HIF-2α-IN-18 is a selective HIF-2α inhibitor with a human IC50 of 8.1 nM. HIF-2α-IN-18 binds to the HIF-2α PAS-B domain, induces conformational perturbations at the HIF-2α/ARNT dimerization interface, destabilizes the HIF-2α/ARNT heterodimer, and blocks HIF-2α-mediated transcriptional activity. HIF-2α-IN-18 inhibits hypoxia-induced expression of HIF-2α target genes EPO and SERPINE1, without inhibiting HIF-1α target genes PGK1 and PDK1. HIF-2α-IN-18 can be used for the research of clear cell renal cell carcinoma, hepatocellular carcinoma[1].
    HIF-2α-IN-18
  • HY-183589
    Ferroptosis-IN-26

    		Ferroptosis Reactive Oxygen Species (ROS) Metabolic Disease
    Ferroptosis-IN-26 is a CEPT1-targeting ferroptosis inhibitor. Ferroptosis-IN-26 enhances CEPT1-dependent phosphatidylcholine remodeling to enrich cellular membranes with monounsaturated fatty acid-containing phosphatidylcholine (PC-MUFA). Ferroptosis-IN-26 suppresses lipid peroxidation. Ferroptosis-IN-26 can be used for the research of acute liver injury .
    Ferroptosis-IN-26
  • HY-185484
    MDX-1203

    BMS-936561

    		 Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Cancer
    MDX-1203 (BMS-936561) is an antibody-drug conjugate targeting CD70. MDX-1203 binds to CD70 and mediates the specific delivery of its conjugated cytotoxic payload to tumors. MDX-1203 delivers a DNA alkylating payload into cells. MDX-1203 can be used in research related to advanced clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma .
    MDX-1203

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: